According to a new report, published by KBV research, The Global Sepsis Diagnostics Market size is expected to reach $879.5 million by 2028, rising at a market growth of 8.3% CAGR during the forecast period.
The Conventional segment acquired maximum revenue share in the Global Sepsis Diagnostics Market by Method in 2021, thereby, achieving a market value of $538.7 million by 2028. The growth of this segment is owing to the increasing requirement for early detection of sepsis in order to streamline the treatment of the disease. Early detection of sepsis and prompt treatment intervention is critical for enhancing clinical outcomes and lowering death rate. Traditionally, sepsis has been diagnosed through serum analysis and molecular techniques. The diagnosis of sepsis is made more difficult by nonspecific signs and symptoms, and it can be difficult because there is no clear standard test that can confirm the diagnosis. A blood culture test is the most common approach for detecting infectious microorganisms in circulation. Aside from that, numerous molecular techniques, such as polymerase chain reaction (PCR), isothermal amplification methods, hybridization techniques, and microarray, are employed to detect infection-causing pathogens, each with a varied sensitivity and specificity.
The Point-of-Care Tests segment is showcasing a CAGR of 10.8% during (2022 - 2028). The rising growth of the segment is owing to the development of novel point-of-care (POC) solutions for sepsis detection. Thermo Fisher Scientific Inc., a diagnostic solutions supplier unveiled its new BRAHMS PCT, a direct point of care test developed for the early identification of bacterial infection and sepsis.
The Bacterial Sepsis segment is leading the Global Sepsis Diagnostics Market by Pathogen in 2021, thereby, achieving a market value of $324.4 million by 2028. This surge can be related to an increase in bacterial sepsis cases, surgical operations, and the prevalence of HAIs. Gram-negative bacteria cause sepsis and septic shock by releasing endotoxin, a cell-wall component (lipopolysaccharide). The lipid is a type of fat. A component found in gram-negative bacteria is immunogenic and believed to be responsible for many of endotoxin's physiologic effects.
The Blood Culture Media segment dominated the Global Sepsis Diagnostics Market by Product in 2021, thereby, achieving a market value of $368.7 million by 2028. The growth of blood culture media segment can be linked to a rise in the number of blood culture media in the market, along with the adoption of blood culture media by hospitals and pathological laboratories for the diagnosis of sepsis. This is because clinicians perceive blood culture to be the most accessible and cost-effective technique of diagnostics.
The Hospitals & specialty clinics segment is generating high revenue in the Global Sepsis Diagnostics Market by End-User in 2021, thereby, achieving a market value of $394.9 million by 2028. Clinical pathology also known as laboratory medicine, is the research and diagnosis of disease through the check-up of urine, blood, and tissue samples. Clinical pathology and reference laboratories provide results such as blood counts, blood coagulation, and electrolyte values, among various other things.
The Biomarkers market has shown growth rate of 8.1% during (2022 - 2028). The multiple advantages offered by this technology in the diagnosis of sepsis, as well as the increasing necessity early disease diagnosis, might be contributed to the expansion of this market. Other biomarkers, such as indicators of the hyper-inflammatory process of sepsis, pro-inflammatory cytokines and chemokines, proteins such as C-reactive protein and procalcitonin, which are polymerized in reaction to infectious disease and in?ammatory and markers of neutrophil and monocyte activation, may help to enhance lactate's effectiveness.
The North America is the fastest growing region in the Global Sepsis Diagnostics Market by Region in 2021, and would continue to be a dominant market till 2018; thereby, achieving a market value of $313.7 million by 2028. The Europe market is estimated to witness a CAGR of 7.6% during (2022 - 2028). Additionally, The Asia Pacific market would exhibit a CAGR of 9.3% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/sepsis-diagnostics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Bruker Corporation, Siemens Healthineers AG, Danaher Corporation, and Quidel Corporation.
By Method
By Test Type
By Pathogen
By Product
By End-User
By Technology
By Geography
Companies Profiled
Unique Offerings 
